

## 13 Bibliography

1. Green, A. I. (2006) Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. *Journal of Clinical Psychiatry*, 67 Suppl 7, 31-5; quiz 6-7.
2. Kavanagh, D. J., McGrath J., Saunders J. B., Dore G., Clark D. (2002) Substance misuse in patients with schizophrenia: epidemiology and management. *Drugs*, 62, 743-55.
3. Grilo, C. M., Sinha R., O'Malley S S. Eating disorders and alcohol use disorders. In: Health, ed. 2002:151-60.
4. Degenhardt, L., Hall W., Lynskey M. (2003) Exploring the association between cannabis use and depression. *Addiction*, 98, 1493-504.
5. Harder, V. S., Morral A. R., Arkes J. (2006) Marijuana use and depression among adults: Testing for causal associations. *Addiction*, 101, 1463-72.
6. Patton, G. C., Coffey C., Carlin J. B., Degenhardt L., Lynskey M., Hall W. (2002) Cannabis use and mental health in young people: cohort study. *British Medical Journal*, 325, 1195-8.
7. Buckner, J. D., Bonn-Miller M. O., Zvolensky M. J., Schmidt N. B. (2007) Marijuana use motives and social anxiety among marijuana-using young adults. *Addictive Behaviors*, 32, 2238-52.
8. Buckner, J. D., Mallott M. A., Schmidt N. B., Taylor J. (2006) Peer influence and gender differences in problematic cannabis use among individuals with social anxiety. *Journal of Anxiety Disorders*, 20, 1087-102.
9. Hayatbakhsh, M. R., Najman J. M., Jamrozik K., Mamun A. A., Alati R., Bor W. (2007) Cannabis and anxiety and depression in young adults: a large prospective study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 46, 408-17.
10. Lipschitz, D. S., Rasmussen A. M., Anyan W., Gueorguieva R., Billingslea E. M., Cromwell P. F. *et al.* (2003) Posttraumatic stress disorder and substance use in inner-city adolescent girls. *The Journal of Nervous and Mental Disease*, 191, 714-21.
11. Sareen, J., Chartier M., Paulus M. P., Stein M. B. (2006) Illicit drug use and anxiety disorders: findings from two community surveys. *Psychiatry Research*, 142, 11-7.
12. Zvolensky, M. J., Bernstein A., Sachs-Ericsson N., Schmidt N. B., Buckner J. D., Bonn-Miller M. O. (2006) Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. *Journal of Psychiatric Research*, 40, 477-86.
13. Zvolensky, M. J., Bonn-Miller M. O., Bernstein A., McLeish A. C., Feldner M. T., Leen-Feldner E. W. (2006) Anxiety sensitivity interacts with marijuana use in the prediction of anxiety symptoms and panic-related catastrophic thinking among daily tobacco users. *Behaviour Research and Therapy*, 44, 907-24.
14. D'Souza, D. C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y. T. *et al.* (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology*, 29, 1558-72.
15. Krystal, J. H., D'Souza D. C., Madonick S., Petrakis I. L. (1999) Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. *Schizophrenia Research*, 35 Suppl, S35-S49.
16. Haw, C., Houston K., Townsend E., Hawton K. (2001) Deliberate self-harm patients with alcohol disorders: characteristics, treatment, and outcome. *Crisis*, 22, 93-101.
17. Manwell, L. B., Czabala J. C., Ignaczak M., Mundt M. P. (2004) Correlates of depression among heavy drinkers in Polish primary care clinics. *International Journal of Psychiatry in Medicine*, 34, 165-78.

18. Abrams, K., Kushner M., Medina K. L., Voight A. (2001) The pharmacologic and expectancy effects of alcohol on social anxiety in individuals with social phobia. *Drug and Alcohol Dependence*, 64, 219-31.
19. Liappas, J., Paparrigopoulos T., Tzavellas E., Christodoulou G. (2003) Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. *Journal of Affective Disorders*, 76, 279-84.
20. Schuckit, M. A., Tipp J. E., Bergman M., Reich W., Hesselbrock V. M., Smith T. L. (1997) Comparison of induced and independent major depressive disorders in 2,945 alcoholics. *The American Journal of Psychiatry*, 154, 948-57.
21. Schuckit, M. A., Tipp J. E., Bucholz K. K., Nurnberger J. I., Jr., Hesselbrock V. M., Crowe R. R. *et al.* (1997) The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. *Addiction*, 92, 1289-304.
22. Sinha, R., Robinson J., O'Malley S. (1998) Stress response dampening: effects of gender and family history of alcoholism and anxiety disorders. *Psychopharmacology (Berl)*, 137, 311-20.
23. Ste-Marie, C., Gupta R., Derevensky J. L. (2006) Anxiety and social stress related to adolescent gambling behavior and substance use. *Journal of Child and Adolescent Substance Use*, 15, 55-74.
24. Ahmadi, J., Farrashbandi H., Majdi B., Mahdavi S., Babaee M. A., Menzies P. *et al.* (2005) Prevalence of Mood and Anxiety Disorders in a Sample of Iranian Outpatient Opioid Addicts. *German Journal of Psychiatry*, 5-7.
25. Ahmadi, M., Ahmadi J. (2005) Substance-Induced Anxiety Disorder In Opioid Dependents. *Addictive Disorders and Their Treatment*, 4, 157-9.
26. Darke, S., Ross J., Williamson A., Mills K. L., Havard A., Teesson M. (2007) Patterns and correlates of attempted suicide by heroin users over a 3-year period: findings from the Australian treatment outcome study. *Drug and Alcohol Dependence*, 87, 146-52.
27. Wild, T. C., el-Guebaly N., Fischer B., Brissette S., Brochu S., Bruneau J. *et al.* (2005) Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study. *Canadian Journal of Psychiatry*, 50, 512-8.
28. Clark, H. W., Masson C. L., Delucchi K. L., Hall S. M., Sees K. L. (2001) Violent traumatic events and drug abuse severity. *Journal of Substance Abuse Treatment*, 20, 121-7.
29. Valentiner, D. P., Mounts N. S., Deacon B. J. (2004) Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. *Journal of Anxiety Disorders*, 18, 573-85.
30. Curran, C., Byrappa N., McBride A. (2004) Stimulant psychosis: systematic review. *The British Journal of Psychiatry*, 185, 196-204.
31. Krystal, J. H., Perry E. B., Jr., Gueorguieva R., Belger A., Madonick S. H., Abi-Dargham A. *et al.* (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. *Archives of General Psychiatry*, 62, 985-94.
32. Landabaso, M. A., Iraurgi I., Jimenez-Lerma J. M., Calle R., Sanz J., Gutierrez-Fraile M. (2002) Ecstasy-induced psychotic disorder: six-month follow-up study. *European Addiction Research*, 8, 133-40.
33. Lin, S. K., Ball D., Hsiao C. C., Chiang Y. L., Ree S. C., Chen C. K. (2004) Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. *Psychiatry and Clinical Neurosciences*, 58, 206-12.
34. Ujike, H. (2002) Stimulant-induced psychosis and schizophrenia: the role of sensitization. *Current Psychiatry Reports*, 4, 177-84.
35. Ujike, H., Sato M. (2004) Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. *Annals of the New York Academy of Sciences*, 1025, 279-87.

36. Yui, K., Ikemoto S., Goto K., Nishijima K., Yoshino T., Ishiguro T. (2002) Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: susceptibility to psychotic states and implications for relapse of schizophrenia. *Pharmacopsychiatry*, 35, 62-71.
37. Yui, K., Ikemoto S., Ishiguro T., Goto K. (2000) Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. *Annals of the New York Academy of Sciences*, 914, 1-12.
38. Yui, K., Ishiguro T., Goto K., Ikemoto S., Kamata Y. (1999) Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. *European Archives of Psychiatry and Clinical Neuroscience*, 249, 103-11.
39. Curran, H. V., Travill R. A. (1997) Mood and cognitive effects of +/-3,4-methylenedioxyamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. *Addiction*, 92, 821-31.
40. Falck, R. S., Carlson R. G., Wang J., Siegal H. A. (2006) Psychiatric disorders and their correlates among young adult MDMA users in Ohio. *Journal of Psychoactive Drugs*, 38, 19-29.
41. Falck, R. S., Wang J., Carlson R. G., Siegal H. A. (2006) Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio. *Addictive Behaviors*, 31, 90-101.
42. Gerra, G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R. et al. (1998) Serotonergic function after (+/-)3,4-methylene-dioxyamphetamine ('Ecstasy') in humans. *International Clinical Psychopharmacology*, 13, 1-9.
43. Lamers, C. T., Bechara A., Rizzo M., Ramaekers J. G. (2006) Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. *Journal of Psychopharmacology*, 20, 302-11.
44. MacInnes, N., Handley S. L., Harding G. F. (2001) Former chronic methylenedioxyamphetamine (MDMA or ecstasy) users report mild depressive symptoms. *Journal of Psychopharmacology*, 15, 181-6.
45. McCardle, K., Luebbers S., Carter J. D., Croft R. J., Stough C. (2004) Chronic MDMA (ecstasy) use, cognition and mood. *Psychopharmacology (Berl)*, 173, 434-9.
46. McGregor, C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J. M. (2005) The nature, time course and severity of methamphetamine withdrawal. *Addiction*, 100, 1320-9.
47. Parrott, A. C. (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. *Human Psychopharmacology*, 16, 557-77.
48. Parrott, A. C., Lasky J. (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)*, 139, 261-8.
49. Peck, J. A., Reback C. J., Yang X., Rotheram-Fuller E., Shoptaw S. (2005) Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. *Journal of Urban Health*, 82, i100-i8.
50. Soar, K., Turner J. J., Parrott A. C. (2006) Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. *Journal of Psychopharmacology*, 20, 417-24.
51. Sumnall, H. R., Cole J. C. (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. *Journal of Psychopharmacology*, 19, 84-92.
52. Verheyden, S. L., Hadfield J., Calin T., Curran H. V. (2002) Sub-acute effects of MDMA (+/-3,4-methylenedioxyamphetamine, "ecstasy") on mood: evidence of gender differences. *Psychopharmacology (Berl)*, 161, 23-31.
53. Vincent, N., Schoobridge J., Ask A., Allsop S., Ali R. (1998) Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. *Drug and Alcohol Review*, 17, 187-95.

54. Williamson, S., Gossop M., Powis B., Griffiths P., Fountain J., Strang J. (1997) Adverse effects of stimulant drugs in a community sample of drug users. *Drug and Alcohol Dependence*, 44, 87-94.
55. Huizink, A. C., Ferdinand R. F., van der Ende J., Verhulst F. C. (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. *British Medical Journal*, 332, 825-8.
56. Parrott, A. C., Buchanan T., Scholey A. B., Heffernan T., Ling J., Rodgers J. (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. *Human Psychopharmacology*, 17, 309-12.
57. Helmus, T. C., Tancer M., Johanson C. E. (2005) Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. *Experimental and Clinical Psychopharmacology*, 13, 348-56.
58. Kasper, S., Resinger E. (2001) Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. *European Neuropsychopharmacology*, 11, 307-21.
59. Nelson, J., Chouinard G. (1999) Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. *The Canadian Journal of Clinical Pharmacology*, 6, 69-83.
60. Duggal, H. S., Sinha B. N., Nizamie S. H. (2000) Gasoline inhalation dependence and bipolar disorder. *The Australian and New Zealand Journal of Psychiatry*, 34, 531-2.
61. Jung, I. K., Lee H. J., Cho B. H. (2004) Persistent psychotic disorder in an adolescent with a past history of butane gas dependence. *European Psychiatry*, 19, 519-20.
62. Shu, L. R., Tsai S. J. (2003) Long-term glue sniffing: report of six cases. *International Journal of Psychiatry in Medicine*, 33, 163-8.
63. Kubik, M. Y., Lytle L. A., Birnbaum A. S., Murray D. M., Perry C. L. (2003) Prevalence and correlates of depressive symptoms in young adolescents. *American Journal of Health Behavior*, 27, 546-53.
64. Ridenour, T. A. (2005) Inhalants: not to be taken lightly anymore. *Current Opinion in Psychiatry*, 18, 243-7.
65. National Inhalant Abuse Taskforce, D. P. a. S. B., Victorian Department of Human Services. National Directions On Inhalant Abuse Final report. In: Ageing Ha, ed. Melbourne: Victorian Government Department of Human Services 2006.
66. Zwar, N., Richmond R., Borland R., Stillman S., Cunningham M., Litt J. Smoking Cessation Guidelines for Australian General Practice. In: Ageing Ha, ed. 2004.
67. Jablensky, A., McGrath J., Herrman H., Castle D., Gureje O., Morgan V. *et al.* People with psychotic illness: An Australian study 1997-98. An overview, National Mental Health Strategy. 1999.
68. McLennan, W. Mental Health and Wellbeing: Profile of Adults, Australia. In: Statistics ABo, ed. Canberra: Australian Government Publishing Service 1997.
69. Jorm, A. F. (1999) Association between smoking and mental disorders: results from an Australian National Prevalence Survey. *Australian and New Zealand Journal of Public Health*, 23, 245-8.
70. Ragg, M., Ahmed T. (2007) Smoking and Mental Health: A review of the literature.
71. Adler, L. E., Hoffer L. D., Wisner A., Freedman R. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. *The American Journal of Psychiatry*, 150, 1856-61.
72. Buckley, T. C., Holohan D. R., Mozley S. L., Walsh K., Kassel J. (2007) The effect of nicotine and attention allocation on physiological and self-report measures of induced anxiety in PTSD: a double-blind placebo-controlled trial. *Experimental and Clinical Psychopharmacology*, 15, 154-64.
73. Feldner, M. T., Babson K. A., Zvolensky M. J. (2007) Smoking, traumatic event exposure, and post-traumatic stress: a critical review of the empirical literature. *Clinical Psychology Review*, 27, 14-45.

74. Feldner, M. T., Babson K. A., Zvolensky M. J., Vujanovic A. A., Lewis S. F., Gibson L. E. *et al.* (2007) Posttraumatic stress symptoms and smoking to reduce negative affect: an investigation of trauma-exposed daily smokers. *Addictive Behaviors*, 32, 214-27.
75. Lyon, E. R. (1999) A review of the effects of nicotine on schizophrenia and antipsychotic medications. *Psychiatric Services*, 50, 1346-50.
76. McNeill, A. (2001) Smoking and mental health: A review of the literature. Smoke Free London and Action on Smoking and Health.
77. Barnes, M., Lawford B. R., Burton S. C., Heslop K. R., Noble E. P., Hausdorf K. *et al.* (2006) Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? *The Australian and New Zealand Journal of Psychiatry*, 40, 575-80.
78. Anzengruber, D., Klump K. L., Thornton L., Brandt H., Crawford S., Fichter M. M. *et al.* (2006) Smoking in eating disorders. *Eating Behaviors*, 7, 291-9.
79. George, A., Waller G. (2005) Motivators for Smoking in Women with Eating Disorders. *European Eating Disorders Review*, 13, 417-23.
80. Maldonado-Molina, M. M., Komro K. A., Prado G. (2007) Prospective association between dieting and smoking initiation among adolescents. *American Journal of Health Promotion*, 22, 25-32.
81. White, M. A., McKee S. A., O'Malley S S. (2007) Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight. *Addictive Behaviors*, 32, 2200-10.
82. Benowitz, N. L. *Nicotine Safety and Toxicity: Oxford University Press* 1998.
83. Lubman, D. I., Sundram S. (2003) Substance misuse in patients with schizophrenia: a primary care guide. *Medical Journal of Australia*, 178 Suppl, S71-5.
84. NSW Health Department, N. S. W. H. D. Guide for the management of nicotine dependent inpatients: summary of evidence. 2002.
85. Ashton, M. E., Weston M. K. A Smoking Cessation Program for People with Mental Illness. *The Australian and New Zealand Mental Health Services Conference*. Sydney, Australia 2002.
86. Ashton, M. E., Weston M. K., Condon S. Tobacco and mental illness project. Adelaide: The Queen Elizabeth Hospital 1998-1999.
87. Lawn, S. J. Systemic barriers to quitting smoking among institutionalised public mental health service populations. Adelaide: Flinders University of South Australia; 2001.
88. Lucksted, A., Dixon L. B., Sembly J. B. (2000) A Focus Group Pilot Study of Tobacco Smoking Among Psychosocial Rehabilitation Clients. *Psychiatric Services*, 51, 1544-8.
89. Lawn, S. J. (2001) Australians with mental illness who smoke. *The British Journal of Psychiatry*, 178, 85.
90. Lawn, S. J., Pols R. G., Barber J. G. (2002) Smoking and Quitting: A Qualitative Study with Community-Living Psychiatric Clients. *Social Science and Medicine*, 1, 93-104.
91. Prochaska, J. J., Rossi J. S., Redding C. A., Rosen A. B., Tsoh J. Y., Humfleet G. L. *et al.* (2004) Depressed smokers and stage of change: implications for treatment interventions. *Drug and Alcohol Dependence*, 76, 143-51.
92. Brown, R. A., Kahler C. W., Niaura R., Abrams D. B., Sales S. D., Ramsey S. E. *et al.* (2001) Cognitive-behavioral treatment for depression in smoking cessation. *Journal of Consulting and Clinical Psychology*, 69, 471-80.
93. Chou, K. R., Chen R., Lee J. F., Ku C. H., Lu R. B. (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. *International Journal of Nursing Studies*, 41, 321-30.
94. Cox, L. S., Patten C. A., Niaura R. S., Decker P. A., Rigotti N., Sachs D. P. *et al.* (2004) Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. *Journal of General Internal Medicine*, 19, 828-34.

95. Evins, A. E., Cather C., Rigotti N. A., Freudenreich O., Henderson D. C., Olm-Shipman C. M. *et al.* (2004) Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. *Journal of Clinical Psychiatry*, 65, 307-11; quiz 452-3.
96. George, T. P., Vessicchio J. C., Sacco K. A., Weinberger A. H., Dudas M. M., Allen T. M. *et al.* (2007) A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia. *Biological Psychiatry*.
97. George, T. P., Vessicchio J. C., Termine A., Bregartner T. A., Feingold A., Rounsaville B. J. *et al.* (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. *Biological Psychiatry*, 52, 53-61.
98. Hall, S. M., Tsoh J. Y., Prochaska J. J., Eisendrath S., Rossi J. S., Redding C. A. *et al.* (2006) Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. *American Journal of Public Health*, 96, 1808-14.
99. Hertzberg, M. A., Moore S. D., Feldman M. E., Beckham J. C. (2001) A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. *Journal of Clinical Psychopharmacology*, 21, 94-8.
100. Horn, K., Dino G., Kalsekar I., Massey C. J., Manzo-Tennant K., McGloin T. (2004) Exploring the relationship between mental health and smoking cessation: a study of rural teens. *Prevention Science*, 5, 113-26.
101. Kisely, S., Campbell L. A. (2008) Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers. *CNS Drugs*, 22, 263-73.
102. Bobo, J. K., McIlvain H. E., Lando H. A., Walker R. D., Leed-Kelly A. (1998) Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. *Addiction*, 93, 877-87.
103. Hitsman, B., Abrams D. B., Shadel W. G., Niaura R., Borrelli B., Emmons K. M. *et al.* (2002) Depressive symptoms and readiness to quit smoking among cigarette smokers in outpatient alcohol treatment. *Psychology of Addictive Behaviors*, 16, 264-8.
104. Begg, S., Vos T., Barker B., Stevenson C., Stanley L., Lopez A. D. The burden of disease and injury in Australia 2003. In: Welfare AloHa, ed. Canberra 2007.
105. Prochaska, J. J., Delucchi K., Hall S. M. (2004) A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. *Journal of Consulting and Clinical Psychology*, 72, 1144-56.
106. Reid, M. S., Fallon B., Sonne S., Flammio F., Nunes E. V., Jiang H. *et al.* (2007) Smoking cessation treatment in community-based substance abuse rehabilitation programs. *Journal of Substance Abuse Treatment*.
107. El-Guebaly, N., Cathcart J., Currie S., Brown D., Gloster S. (2002) Smoking cessation approaches for persons with mental illness or addictive disorders. *Psychiatric Services*, 53, 1166-70.
108. Lee, N., Coonan D., Dunlop A., Stephens R., Ritter A. Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 12: Smoking cessation - working with clients to quit. In: Inc TPAaDC, ed. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre Inc 2005.
109. Bozikas, V. P., Papakosta M., Niopas I., Karavatos A., Mirtsou-Fidani V. (2004) Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. *European Neuropsychopharmacology*, 14, 39-44.
110. Ozdemir, V., Kalow W., Posner P., Collins E. J., Kennedy J. L., Tang B. K. *et al.* (2001) CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. *Journal of Clinical Psychopharmacology*, 21, 398-407.
111. Taylor, D. (1997) Pharmacokinetic interactions involving clozapine. *The British Journal of Psychiatry*, 171, 109-12.

112. Callaghan, J. T., Bergstrom R. F., Ptak L. R., Beasley C. M. (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. *Clinical Pharmacokinetics*, 37, 177-93.
113. Carrillo, J. A., Herraiz A. G., Ramos S. I., Gervasini G., Vizcaino S., Benitez J. (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. *Journal of Clinical Psychopharmacology*, 23, 119-27.
114. Addington, J. (1998) Group treatment for smoking cessation among persons with schizophrenia. *Psychiatric Services*, 49, 925-8.
115. Association, A. P. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text Revision ed. Washington: American Psychiatric Association 2000.
116. Practitioners, T. R. A. C. o. G. (2006) Putting Prevention into practice: Guidelines for the implantation of prevention in the general practice setting. South Melbourne: The Royal Australian College of General Practitioners.
117. Silagy, C., Lancaster T., Stead L., Mant D., Fowler G. (2001) Nicotine replacement Therapy for Smoking Cessation. *Cochrane Database of Systematic Reviews*.
118. Jorenby, D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. *et al.* (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *The Journal of the American Medical Association*, 296, 56-63.
119. Aalto-Setälä, T., Marttunen M., Tuulio-Henriksson A., Poikolainen K., Lonnqvist J. (2001) One-month prevalence of depression and other DSM-IV disorders among young adults. *Psychological Medicine*, 31, 791-801.
120. Landheim, A. S., Bakken K., Vaglum P. (2003) Gender differences in the prevalence of symptom disorders and personality disorders among poly-substance abusers and pure alcoholics. Substance abusers treated in two counties in Norway. *European Addiction Research*, 9, 8-17.
121. Melartin, T. K., Rytysala H. J., Leskela U. S., Lestela-Mielonen P. S., Sokero T. P., Isometsa E. T. (2002) Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. *Journal of Clinical Psychiatry*, 63, 126-34.
122. Vuorilehto, M., Melartin T., Isometsa E. (2005) Depressive disorders in primary care: recurrent, chronic, and co-morbid. *Psychological Medicine*, 35, 673-82.
123. Carey, P. D., Stein D. J., Zungu-Dirwayi N., Seedat S. (2003) Trauma and posttraumatic stress disorder in an urban Xhosa primary care population: prevalence, comorbidity, and service use patterns. *The Journal of Nervous and Mental Disease*, 191, 230-6.
124. Zimmerman, M., Chelminski I. (2003) Generalized anxiety disorder in patients with major depression: is DSM-IV's hierarchy correct? *The American Journal of Psychiatry*, 160, 504-12.
125. Nunes, E. V., Levin F. R. (2004) Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. *The Journal of the American Medical Association*, 291, 1887-96.
126. van Laar, M., van Dorsselaer S., Monshouwer K., de Graaf R. (2007) Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? *Addiction*, 102, 1251-60.
127. Hall, M., Buckley N. (2003) Serotonin Syndrome. *Australian Prescriber*, 26, 62-3.
128. Denis, C., Lavie E., Fatseas M., Auriacombe M. (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. *Cochrane Database of Systematic Reviews*, 3, CD005336.
129. Preuss, U. W., Schuckit M. A., Smith T. L., Danko G. R., Dasher A. C., Hesselbrock M. N. *et al.* (2002) A comparison of alcohol-induced and independent depression in alcoholics with histories of suicide attempts. *Journal of Studies on Alcohol*, 63, 498-502.

130. Cornelius, J. R., Salloum I. M., Ehler J. G., Jarrett P. J., Cornelius M. D., Perel J. M. *et al.* (1997) Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. *Archives of General Psychiatry*, 54, 700-5.
131. Sher, L. (2006) Alcoholism and suicidal behavior: a clinical overview. *Acta Psychiatrica Scandinavica*, 113, 13-22.
132. McKeon, A., Frye M. A., Delanty N. (2007) The Alcohol Withdrawal Syndrome. *Journal of Neurology, Neurosurgery, and Psychiatry*.
133. Tassaneeyakul, W., Birkett D. J., Miners J. O. (1998) Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. *Xenobiotica*, 28, 293-301.
134. Salloum, I. M., Cornelius J. R., Thase M. E., Daley D. C., Kirisci L., Spotts C. (1998) Naltrexone utility in depressed alcoholics. *Psychopharmacology Bulletin*, 34, 111-5.
135. Roy, A. (1998) Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. *Biological Psychiatry*, 44, 633-7.
136. Cornelius, J. R., Bukstein O. G., Birmaher B., Salloum I. M., Lynch K., Pollock N. K. *et al.* (2001) Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. *Addictive Behaviors*, 26, 735-9.
137. Yoon, S. J., Pae C. U., Kim D. J., Namkoong K., Lee E., Oh D. Y. *et al.* (2006) Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 30, 1196-201.
138. Chick, J., Aschauer H., Hornik K. (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. *Drug and Alcohol Dependence*, 74, 61-70.
139. Pettinati, H. M., Volpicelli J. R., Kranzler H. R., Luck G., Rukstalis M. R., Cnaan A. (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. *Alcoholism: Clinical and Experimental Research*, 24, 1041-9.
140. Ramsey, S. E., Brown R. A., Stuart G. L., Burgess E. S., Miller I. W. (2002) Cognitive variables in alcohol dependent patients with elevated depressive symptoms: changes and predictive utility as a function of treatment modality. *Substance Abuse*, 23, 171-82.
141. Kranzler, H. R., Van Kirk J. (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. *Alcoholism: Clinical and Experimental Research*, 25, 1335-41.
142. Miotto, K., McCann M., Basch J., Rawson R., Ling W. (2002) Naltrexone and dysphoria: fact or myth? *The American Journal on Addictions*, 11, 151-60.
143. Oslin, D. W. (2005) Treatment of late-life depression complicated by alcohol dependence. *The American Journal of Geriatric Psychiatry*, 13, 491-500.
144. Kiefer, F., Helwig H., Tarnaske T., Otte C., Jahn H., Wiedemann K. (2005) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. *European Addiction Research*, 11, 83-91.
145. Krystal, J. H., Gueorguieva R., Cramer J., Collins J., Rosenheck R. (2008) Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". *Alcoholism: Clinical and Experimental Research*, 32, 85-91.
146. Dean, A. J., Bell J., Christie M. J., Mattick R. P. (2004) Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. *European Psychiatry*, 19, 510-3.

147. Stein, M. D., Herman D. S., Solomon D. A., Anthony J. L., Anderson B. J., Ramsey S. E. *et al.* (2004) Adherence to treatment of depression in active injection drug users: the minerva study. *Journal of Substance Abuse Treatment*, 26, 87-93.
148. Eap, C. B., Bertschy G., Powell K., Baumann P. (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. *Journal of Clinical Psychopharmacology*, 17, 113-7.
149. Eap, C. B., Buclin T., Baumann P. (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. *Clinical Pharmacokinetics*, 41, 1153-93.
150. Iribarne, C., Picart D., Dreano Y., Berthou F. (1998) In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. *Fundamental and Clinical Pharmacology*, 12, 194-9.
151. Ballesteros, M. F., Budnitz D. S., Sanford C. P., Gilchrist J., Agyekum G. A., Butts J. (2003) Increase in deaths due to methadone in North Carolina. *The Journal of the American Medical Association*, 290, 40.
152. Buster, M. C., van Brussel G. H., van den Brink W. (2002) An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. *Addiction*, 97, 993-1001.
153. Caplehorn, J. R., Drummer O. H. (1999) Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. *Medical Journal of Australia*, 170, 104-9.
154. Williamson, P. A., Foreman K. J., White J. M., Anderson G. (1997) Methadone-related overdose deaths in South Australia, 1984-1994. How safe is methadone prescribing? *Medical Journal of Australia*, 166, 302-5.
155. Zador, D., Sunjic S. (2000) Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. *Addiction*, 95, 77-84.
156. Hamilton, S. P., Nunes E. V., Janal M., Weber L. (2000) The effect of sertraline on methadone plasma levels in methadone-maintenance patients. *The American Journal on Addictions*, 9, 63-9.
157. Benitez-Rosario, M. A., Salinas Martin A., Gomez-Ontanon E., Feria M. (2006) Methadone-induced respiratory depression after discontinuing carbamazepine administration. *Journal of Pain and Symptom Management*, 32, 99-100.
158. Farre, M., Mas A., Torrens M., Moreno V., Cami J. (2002) Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. *Drug and Alcohol Dependence*, 65, 283-90.
159. Joseph, H., Stancliff S., Langrod J. (2000) Methadone maintenance treatment (MMT): a review of historical and clinical issues. *The Mount Sinai Journal of Medicine*, 67, 347-64.
160. Ward, J., Hall W., Mattick R. P. (1999) Role of maintenance treatment in opioid dependence. *Lancet*, 353, 221-6.
161. Burns, J. M., Martyres R. F., Clode D., Boldero J. M. (2004) Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. *Medical Journal of Australia*, 181, S25-8.
162. Carpenter, K. M., Brooks A. C., Vosburg S. K., Nunes E. V. (2004) The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. *Drug and Alcohol Dependence*, 74, 123-34.
163. Dean, A. J., Bell J., Mascord D. J., Parker G., Christie M. J. (2002) A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. *Journal of Affective Disorders*, 72, 85-90.

164. Dean, A. J., Saunders J. B., Jones R. T., Young R. M., Connor J. P., Lawford B. R. (2006) Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. *Journal of Psychiatry and Neuroscience*, 31, 38-45.
165. Petrakis, I., Carroll K. M., Nich C., Gordon L., Kosten T., Rounsaville B. (1998) Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. *Drug and Alcohol Dependence*, 50, 221-6.
166. Modesto-Lowe, V., Van Kirk J. (2002) Clinical uses of naltrexone: a review of the evidence. *Experimental and Clinical Psychopharmacology*, 10, 213-27.
167. de Win, M. M., Reneman L., Reitsma J. B., den Heeten G. J., Booij J., van den Brink W. (2004) Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstinence, dose, and gender. *Psychopharmacology (Berl)*, 173, 376-82.
168. Falck, R. S., Jichuan W., Carlson R. G. (2008) Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis. *Journal of Psychopharmacology*, 22, 47-54.
169. Abraham, H. D., Fava M. (1999) Order of onset of substance abuse and depression in a sample of depressed outpatients. *Comprehensive Psychiatry*, 40, 44-50.
170. Guillot, C., Greenway D. (2006) Recreational ecstasy use and depression. *Journal of Psychopharmacology*, 20, 411-6.
171. Parrott, A. C. (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. *Journal of Psychopharmacology*, 20, 147-63.
172. Baumann, M. H., Wang X., Rothman R. B. (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. *Psychopharmacology (Berl)*, 189, 407-24.
173. Cowan, R.L. (2007) Neuroimaging research in human MDMA users: a review. *Psychopharmacology (Berl)*, 189, 539-56.
174. McCann, U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W. B., Ravert H. T. *et al.* (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [<sup>11</sup>C]McN5652 and [<sup>11</sup>C]DASB. *Neuropsychopharmacology*, 30, 1741-50.
175. Parrott, A. C. (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. *Pharmacology Biochemistry and Behavior*, 71, 837-44.
176. Parrott, A. C., Rodgers J., Buchanan T., Ling J., Heffernan T., Scholey A. B. (2006) Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. *Human Psychopharmacology*, 21, 285-98.
177. Reneman, L., de Win M. M., van den Brink W., Booij J., den Heeten G. J. (2006) Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. *Journal of Psychopharmacology*, 20, 164-75.
178. Parrott, A. C. (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. *Journal of Psychopharmacology*, 19, 71-83.
179. Freezer, A., Salem A., Irvine R. J. (2005) Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. *Brain Research*, 11041, 48-55.
180. Hewton, R., Salem A., Irvine R. J. (2007) Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor. *Clinical and Experimental Pharmacology and Physiology*, 34, 1051-7.

181. NCIS, N. C. I. S. Interactions between amphetamines, ecstasy and anti-depressants. In: *Medicine VloF*, ed. Melbourne 2007.
182. Vuori, E., Henry J. A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P. *et al.* (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. *Addiction*, 98, 365-8.
183. Jaffe, A., Shoptaw S., Stein J., Reback C. J., Rotheram-Fuller E. (2007) Depression ratings, reported sexual risk behaviors, and methamphetamine use: latent growth curve models of positive change among gay and bisexual men in an outpatient treatment program. *Experimental and Clinical Psychopharmacology*, 15, 301-7.
184. Baicy, K., Bearden C. E., Monterosso J., Brody A. L., Isaacson A. J., London E. D. (2005) Common substrates of dysphoria in stimulant drug abuse and primary depression: therapeutic targets. *International Review of Neurobiology*, 65, 117-45.
185. Thase, M. E. (2006) Depression and sleep: pathophysiology and treatment. *Dialogues in Clinical Neuroscience*, 8, 217-26.
186. Pagel, J. F., Parnes B. L. (2001) Medications for the Treatment of Sleep Disorders: An Overview. *Primary Care Companion to the Journal of Clinical Psychiatry*, 3, 118-25.
187. Rijnbeek, B., de Visser S. J., Franson K. L., Cohen A. F., van Gerven J. M. (2003) REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. *Journal of Psychopharmacology*, 17, 196-203.
188. Rosenberg, R. P. (2006) Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. *Annals of Clinical Psychiatry*, 18, 49-56.
189. Chouinard, G. (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. *Journal of Clinical Psychiatry*, 65 7-12.
190. Jacobs, G. D., Pace-Schott E. F., Stickgold R., Otto M. W. (2004) Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. *Archives of Internal Medicine*, 164, 1888-96.
191. Roth, T., Krystal A. D., Lieberman J. A. r. (2007) Long-term issues in the treatment of sleep disorders. *CNS Spectrums*, 12, 1-13.
192. Winkelman, J., Pies R. (2005) Current patterns and future directions in the treatment of insomnia. *Annals of Clinical Psychiatry*, 17, 31-40.
193. Morin, C. M., Bootzin R. R., Buysse D. J., Edinger J. D., Espie C. A., Lichstein K. L. (2006) Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). *Sleep*, 29, 1398-414.
194. Riddle, M. A., Bernstein G. A., Cook E. H., Leonard H. L., March J. S., Swanson J. M. (1999) Anxiolytics, adrenergic agents, and naltrexone. *Journal of the American Academy of Child and Adolescent Psychiatry*, 38, 546-56.
195. Denis, C., Fatseas M., Lavie E., Auriacombe M. (2006) Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. *Cochrane Database of Systematic Reviews*, 3, CD005194.
196. Posternak, M. A., Mueller T. I. (2001) Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. *The American Journal on Addictions*, 10, 48-68.
197. Boothroyd, L. J., Kirmayer L. J., Spreng S., Malus M., Hodgins S. (2001) Completed suicides among the Inuit of northern Quebec, 1982-1996: a case-control study. *Canadian Medical Association Journal*, 165, 749-55.
198. Kelly, T. M., Cornelius J. R., Lynch K. G. (2002) Psychiatric and substance use disorders as risk factors for attempted suicide among adolescents: a case control study. *Suicide and Life-Threatening Behavior*, 32, 301-12.

199. Sakai, J. T., Hall S. K., Mikulich-Gilbertson S. K., Crowley T. J. (2004) Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. *Journal of the American Academy of Child and Adolescent Psychiatry*, 43, 1080-8.
200. Wilcox, H. C., Anthony J. C. (2004) The development of suicide ideation and attempts: an epidemiologic study of first graders followed into young adulthood. *Drug and Alcohol Dependence*, 76 Suppl, S53-S67.
201. Birchall, H., Brandon S., Taub N. (2000) Panic in a general practice population: prevalence, psychiatric comorbidity and associated disability. *Social Psychiatry and Psychiatric Epidemiology*, 35, 235-41.
202. Hofmann, S. G., Smits J. A. (2008) Cognitive-Behavioral Therapy for Adult Anxiety Disorders: A Meta-Analysis of Randomized Placebo-Controlled Trials. *Journal of Clinical Psychiatry*, e1-e12.
203. Gorenstein, E. E., Kleber M. S., Mohlman J., Dejesus M., Gorman J. M., Papp L. A. (2005) Cognitive-behavioral therapy for management of anxiety and medication taper in older adults. *The American Journal of Geriatric Psychiatry*, 13, 901-9.
204. Gosselin, P., Ladouceur R., Morin C. M., Dugas M. J., Baillargeon L. (2006) Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. *Journal of Consulting and Clinical Psychology*, 74, 908-19.
205. Blomhoff, S., Haug T. T., Hellstrom K., Holme I., Humble M., Madsbu H. P. *et al.* (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. *The British Journal of Psychiatry*, 179, 23-30.
206. Davidson, J. R., Foa E. B., Huppert J. D., Keefe F. J., Franklin M. E., Compton J. S. *et al.* (2004) Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. *Archives of General Psychiatry*, 61, 1005-13.
207. Fedoroff, I. C., Taylor S. (2001) Psychological and pharmacological treatments of social phobia: a meta-analysis. *Journal of Clinical Psychopharmacology*, 21, 311-24.
208. Lader, M., Stender K., Burger V., Nil R. (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. *Depression and Anxiety*, 19, 241-8.
209. Lepola, U., Bergholdt B., St Lambert J., Davy K. L., Ruggiero L. (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. *Journal of Clinical Psychiatry*, 65, 222-9.
210. Liebowitz, M. R., DeMartinis N. A., Weihs K., Londborg P. D., Smith W. T., Chung H. *et al.* (2003) Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. *Journal of Clinical Psychiatry*, 64, 785-92.
211. Stein, M. B., Fyer A. J., Davidson J. R., Pollack M. H., Wiita B. (1999) Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. *The American Journal of Psychiatry*, 156, 756-60.
212. Stein, M. B., Liebowitz M. R., Lydiard R. B., Pitts C. D., Bushnell W., Gergel I. (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. *The Journal of the American Medical Association*, 280, 708-13.
213. Van Ameringen, M. A., Lane R. M., Walker J. R., Bowen R. C., Chokka P. R., Goldner E. M. *et al.* (2001) Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. *The American Journal of Psychiatry*, 158, 275-81.
214. Chouinard, G., Goodman W., Greist J., Jenike M., Rasmussen S., White K. *et al.* (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. *Psychopharmacology Bulletin*, 26, 279-84.

215. Greist, J., Chouinard G., DuBoff E., Halaris A., Kim S. W., Koran L. *et al.* (1995) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. *Archives of General Psychiatry*, 52, 289-95.
216. Montgomery, S. A., McIntyre A., Osterheider M., Sarteschi P., Zitterl W., Zohar J. *et al.* (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. *European Neuropsychopharmacology*, 3, 143-52.
217. Pigott, T. A., Pato M. T., Bernstein S. E., Grover G. N., Hill J. L., Tolliver T. J. *et al.* (1990) Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. *Archives of General Psychiatry*, 47, 926-32.
218. Tollefson, G. D., Rampey A. H., Jr., Potvin J. H., Jenike M. A., Rush A. J., Kominguez R. A. *et al.* (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. *Archives of General Psychiatry*, 51, 559-67.
219. Grubaugh, A. L., Magruder K. M., Waldrop A. E., Elhai J. D., Knapp R. G., Frueh B. C. (2005) Subthreshold PTSD in primary care: prevalence, psychiatric disorders, healthcare use, and functional status. *The Journal of Nervous and Mental Disease*, 193, 658-64.
220. Labbate, L. A., Sonne S. C., Randal C. L., Anton R. F., Brady K. T. (2004) Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? *Comprehensive Psychiatry*, 45, 304-10.
221. Magruder, K. M., Frueh B. C., Knapp R. G., Davis L., Hamner M. B., Martin R. H. *et al.* (2005) Prevalence of posttraumatic stress disorder in Veterans Affairs primary care clinics. *General Hospital Psychiatry*, 27, 169-79.
222. Roy-Byrne, P. P., Stein M. B., Russo J., Mercier E., Thomas R., McQuaid J. *et al.* (1999) Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. *Journal of Clinical Psychiatry*, 60, 492-9; quiz 500.
223. Sareen, L., Stein M. (2000) A review of the epidemiology and approaches to the treatment of social anxiety disorder. *Drugs*, 59, 497-509.
224. Stein, M. B., McQuaid J. R., Pedrelli P., Lenox R., McCahill M. E. (2000) Posttraumatic stress disorder in the primary care medical setting. *General Hospital Psychiatry*, 22, 261-9.
225. Bonn-Miller, M. O., Zvolensky M. J., Leen-Feldner E. W., Feldner M. T., Yartz A. R. (2005) Marijuana Use Among Daily Tobacco Smokers: Relationship to Anxiety-Related Factors. *Journal of Psychopathology and Behavioral Assessment*, 27, 279-89.
226. Brady, K. T., Tolliver B. K., Verduin M. L. (2007) Alcohol use and anxiety: diagnostic and management issues. *The American Journal of Psychiatry*, 164, 217-21; quiz 372.
227. Schmidt, N. B., Buckner J. D., Keough M. E. (2007) Anxiety sensitivity as a prospective predictor of alcohol use disorders. *Behavior Modification*, 31, 202-19.
228. Willinger, U., Lenzinger E., Hornik K., Fischer G., Schönbeck G., Aschauer H. N. *et al.* (2002) Anxiety as a Predictor of Relapse in Detoxified Alcohol-Dependent Patients. *Alcohol and Alcoholism*, 37, 609-12.
229. AMH, A. M. H. Australian Medicines Handbook. Adelaide 2007.
230. Saivin, S., Hulot T., Chabac S., Potgieter A., Durbin P., Houin G. (1998) Clinical pharmacokinetics of acamprosate. *Clinical Pharmacokinetics*, 35, 331-45.
231. Schade, A., Marquenie L. A., van Balkom A. J., Koeter M. W., de Beurs E., van den Brink W. *et al.* (2005) The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. *Alcoholism: Clinical and Experimental Research*, 29, 794-800.
232. Thevos, A. K., Roberts J. S., Thomas S. E., Randall C. L. (2000) Cognitive behavioral therapy delays relapse in female socially phobic alcoholics. *Addictive Behaviors*, 25, 333-45.

233. Randall, C. L., Johnson M. R., Thevos A. K., Sonne S. C., Thomas S. E., Willard S. L. *et al.* (2001) Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. *Depression and Anxiety*, 14, 255-62.
234. Brady, K. T., Sonne S., Anton R. F., Randall C. L., Back S. E., Simpson K. (2005) Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. *Alcoholism: Clinical and Experimental Research*, 29, 395-401.
235. Garbutt, J. C., Kranzler H. R., O'Malley S. S., Gastfriend D. R., Pettinati H. M., Silverman B. L. *et al.* (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *The Journal of the American Medical Association*, 293, 1617-25.
236. Kranzler, H. R., Wesson D. R., Billot L. (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research*, 28, 1051-9.
237. Petrakis, I. L., Poling J., Levinson C., Nich C., Carroll K., Ralevski E. *et al.* (2006) Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. *Biological Psychiatry*, 60, 777-83.
238. Hien, D. A., Nunes E., Levin F. R., Fraser D. (2000) Posttraumatic stress disorder and short-term outcome in early methadone treatment. *Journal of Substance Abuse Treatment*, 19, 31-7.
239. Trafton, J. A., Minkel J., Humphreys K. (2006) Opioid substitution treatment reduces substance use equivalently in patients with and without posttraumatic stress disorder. *Journal of Studies on Alcohol*, 67, 228-35.
240. Boulton, D. W., Arnaud P., DeVane C. L. (2001) A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. *British Journal of Clinical Pharmacology*, 51, 350-4.
241. Totah, R. A., Allen K. E., Sheffels P., Whittington D., Kharasch E. D. (2007) Enantiomeric metabolic interactions and stereoselective human methadone metabolism. *The Journal of Pharmacology and Experimental Therapeutics*, 321, 389-99.
242. Thummel, K. E., Wilkinson G. R. (1998) In vitro and in vivo drug interactions involving human CYP3A. *Annual Review of Pharmacology and Toxicology*, 38, 389-430.
243. Zhang, W., Ramamoorthy Y., Tyndale R. F., Sellers E. M. (2003) Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. *Drug Metabolism and Disposition*, 31, 768-72.
244. Kintz, P. (2002) A new series of 13 buprenorphine-related deaths. *Clin Biochem*, 35, 513-6.
245. Lai, S. H., Yao Y. J., Lo D. S. (2006) A survey of buprenorphine related deaths in Singapore. *Forensic Science International*, 162, 80-6.
246. Reynaud, M., Petit G., Potard D., Courty P. (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. *Addiction*, 93, 1385-92.
247. Dyer, K. R., White J. M., Foster D. J., Bochner F., Menelaou A., Somogyi A. A. (2001) The relationship between mood state and plasma methadone concentration in maintenance patients. *Journal of Clinical Psychopharmacology*, 21, 78-84.
248. Gowing, L., Ali R., White J. (2006) Buprenorphine for the management of opioid withdrawal. *Cochrane Database of Systematic Reviews*, CD002025.
249. Evren, C., Barut T., Saatcioglu O., Cakmak D. (2006) Axis I psychiatric comorbidity among adult inhalant dependents seeking treatment. *Journal of Psychoactive Drugs*, 38, 57-64.
250. Wu, L. T., Howard M. O. (2007) Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions. *Drug and Alcohol Dependence*, 88, 146-55.

251. Olfson, M., Lewis-Fernandez R., Weissman M. M., Feder A., Gameraoff M. J., Pilowsky D. *et al.* (2002) Psychotic symptoms in an urban general medicine practice. *The American Journal of Psychiatry*, 159, 1412-9.
252. Leucht, S., Pitschel-Walz G., Abraham D., Kissling W. (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophrenia Research*, 35, 51-68.
253. Wahlbeck, K., Cheine M., Essali A., Adams C. (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. *The American Journal of Psychiatry*, 156, 990-9.
254. Bilder, R. M., Goldman R. S., Volavka J., Czobor P., Hoptman M., Sheitman B. *et al.* (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *The American Journal of Psychiatry*, 159, 1018-28.
255. Green, M. F., Marshall B. D., Jr., Wirshing W. C., Ames D., Marder S. R., McGurk S. *et al.* (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? *The American Journal of Psychiatry*, 154, 799-804.
256. Meltzer, H. Y., McGurk S. R. (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. *Schizophrenia Bulletin*, 25, 233-55.
257. Bowden, C. L., Calabrese J. R., Sachs G., Yatham L. N., Asghar S. A., Hompland M. *et al.* (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Archives of General Psychiatry*, 60, 392-400.
258. Calabrese, J. R., Bowden C. L., Sachs G., Yatham L. N., Behnke K., Mehtonen O. P. *et al.* (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. *Journal of Clinical Psychiatry*, 64, 1013-24.
259. Smith, L. A., Cornelius V., Warnock A., Tacchi M. J., Taylor D. (2007) Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. *Bipolar Disorders*, 9, 551-60.
260. El-Mallakh, R. S., Ketter T. A., Weisler R. H., Hirschfeld R., Cutler A. J., Gazda T. *et al.* (2008) Switching from other agents to extended-release carbamazepine in acute mania. *Psychopharmacology Bulletin*, 41, 52-8.
261. Calabrese, J. R., Huffman R. F., White R. L., Edwards S., Thompson T. R., Ascher J. A. *et al.* (2008) Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. *Bipolar Disorders*, 10, 323-33.
262. Buckley, P. F. (2008) Update on the treatment and management of schizophrenia and bipolar disorder. *CNS Spectrums*, 13, 1-10; quiz 1-2.
263. Gregg, L., Barrowclough C., Haddock G. (2007) Reasons for increased substance use in psychosis. *Clinical Psychology Review*, 27, 494-510.
264. Dubertret, C., Bidard I., Ades J., Gorwood P. (2006) Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. *Schizophrenia Research*, 86, 284-90.
265. Green, A. I., Tohen M. F., Hamer R. M., Strakowski S. M., Lieberman J. A., Glick I. *et al.* (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. *Schizophrenia Research*, 66, 125-35.

266. Goswami, S., Mattoo S. K., Basu D., Singh G. (2004) Substance-abusing schizophrenics: do they self-medicate? *The American Journal on Addictions*, 13, 139-50.
267. San, L., Arranz B., Martinez-Raga J. (2007) Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. *European Addiction Research*, 13, 230-43.
268. Kawa, I., Carter J. D., Joyce P. R., Doughty C. J., Frampton C. M., Wells J. E. *et al.* (2005) Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. *Bipolar Disorders*, 7, 119-25.
269. Wobrock, T., Sittinger H., Behrendt B., D'Amelio R., Falkai P., Caspari D. (2007) Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, 257, 203-10.
270. Drake, R. E., Xie H., McHugo G. J., Green A. I. (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. *Schizophrenia Bulletin*, 26, 441-9.
271. Green, A. I., Noordsy D. L., Brunette M. F., O'Keefe C. (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. *Journal of Substance Abuse Treatment*, 34, 61-71.
272. McEvoy, J. P., Freudenreich O., Wilson W. H. (1999) Smoking and therapeutic response to clozapine in patients with schizophrenia. *Biological Psychiatry*, 46, 125-9.
273. Stuyt, E. B., Sajbel T. A., Allen M. H. (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. *The American Journal on Addictions*, 15, 166-73.
274. Zimmet, S. V., Strous R. D., Burgess E. S., Kohnstamm S., Green A. I. (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. *Journal of Clinical Psychopharmacology*, 20, 94-8.
275. McEvoy, J. P., Lieberman J. A., Stroup T. S., Davis S. M., Meltzer H. Y., Rosenheck R. A. *et al.* (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *The American Journal of Psychiatry*, 163, 600-10.
276. Buckley, P., Thompson P., Way L., Meltzer H. Y. (1994) Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. *The American Journal of Psychiatry*, 151, 385-9.
277. Naeem, F., Kingdon D., Turkington D. (2005) Cognitive behavior therapy for schizophrenia in patients with mild to moderate substance misuse problems. *Cognitive Behaviour Therapy*, 34, 207-15.
278. Barrowclough, C., Haddock G., Tarrrier N., Lewis S. W., Moring J., O'Brien R. *et al.* (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. *The American Journal of Psychiatry*, 158, 1706-13.
279. Grace, R. F., Shenfield G., Tennant C. (2000) Cannabis and psychosis in acute psychiatric admissions. *Drug and Alcohol Review*, 19, 287-90.
280. Wittchen, H. U., Frohlich C., Behrendt S., Gunther A., Rehm J., Zimmermann P. *et al.* (2007) Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. *Drug and Alcohol Dependence*, 88 Suppl 1, S60-S70.
281. Strakowski, S. M., DelBello M. P., Fleck D. E., Arndt S. (2000) The impact of substance abuse on the course of bipolar disorder. *Biological Psychiatry*, 48, 477-85.
282. Boydell, J., van Os J., Caspi A., Kennedy N., Giouroukou E., Fearon P. *et al.* (2006) Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. *Psychological Medicine*, 36, 1441-6.

283. de Irala, J., Ruiz-Canela M., Martinez-Gonzalez M. A. (2005) Causal relationship between cannabis use and psychotic symptoms or depression. Should we wait and see? A public health perspective. *Medical Science Monitor*, 11, RA355-RA8.
284. Fergusson, D. M., Horwood L. J., Ridder E. M. (2005) Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*, 100, 354-66.
285. Semple, D. M., McIntosh A. M., Lawrie S. M. (2005) Cannabis as a risk factor for psychosis: systematic review. *Journal of Psychopharmacology*, 19, 187-94.
286. Degenhardt, L., Hall W., Lynskey M. (2003) Testing hypotheses about the relationship between cannabis use and psychosis. *Drug and Alcohol Dependence*, 71, 37-48.
287. Miller, P. M., Johnstone E. C., Lawrie S. M., Owens D. G. C. (2006) Substance use, psychiatric symptoms and the onset of schizophrenia illness. *Journal of Substance Use*, 11, 101-13.
288. Degenhardt, L., Tennant C., Gilmour S., Schofield D., Nash L., Hall W. *et al.* (2007) The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. *Psychological Medicine*, 37, 927-34.
289. D'Souza, D. C., Abi-Saab W. M., Madonick S., Forselius-Bielen K., Doersch A., Braley G. *et al.* (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biological Psychiatry*, 57, 594-608.
290. Hall, W., Degenhardt L., Teesson M. (2004) Cannabis use and psychotic disorders: an update. *Drug and Alcohol Review*, 23, 433-43.
291. Isaac, M., Holloway F. (2005) Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. *Human Psychopharmacology*, 20, 207-10.
292. Green, B., Kavanagh D. J., Young R. M. (2004) Reasons for cannabis use in men with and without psychosis. *Drug and Alcohol Review*, 23, 445-53.
293. Schofield, D., Tennant C., Nash L., Degenhardt L., Cornish A., Hobbs C. *et al.* (2006) Reasons for cannabis use in psychosis. The Australian and New Zealand Journal of Psychiatry, 40, 570-4.
294. Zullino, D. F., Delessert D., Eap C. B., Preisig M., Baumann P. (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. *International Clinical Psychopharmacology*, 17, 141-3.
295. Edwards, J., Elkins K., Hinton M., Harrigan S. M., Donovan K., Athanasopoulos O. *et al.* (2006) Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. *Acta Psychiatrica Scandinavica*, 114, 109-17.
296. Green, A. I., Burgess E. S., Dawson R., Zimmet S. V., Strous R. D. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. *Schizophrenia Research*, 60, 81-5.
297. Berk, M., Brook S., Trandafir A. I. (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. *International Clinical Psychopharmacology*, 14, 177-80.
298. Frye, M. A., Salloum I. M. (2006) Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. *Bipolar Disorders*, 8, 677-85.
299. D'Souza, D. C., Gil R. B., Madonick S., Perry E. B., Forselius-Bielen K., Braley G. *et al.* (2006) Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. *Neuropsychopharmacology*, 31, 2767-75.
300. Thoma, R. J., Hanlon F. M., Miller G. A., Huang M., Weisend M. P., Sanchez F. P. *et al.* (2006) Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. *Journal of the International Neuropsychological Society*, 12, 34-44.

301. Murthy, K. K. (1997) Psychosis during disulfiram therapy for alcoholism. *Journal of the Indian Medical Association*, 95, 80-1.
302. Petrakis, I. L., Nich C., Ralevski E. (2006) Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. *Schizophrenia Bulletin*, 32, 644-54.
303. Petrakis, I. L., O'Malley S., Rounsaville B., Poling J., McHugh-Strong C., Krystal J. H. (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. *Psychopharmacology (Berl)*, 172, 291-7.
304. Mueser, K. T., Noordsy D. L., Fox L., Wolfe R. (2003) Disulfiram treatment for alcoholism in severe mental illness. *The American Journal on Addictions*, 12, 242-52.
305. Sorensen, H. J., Jepsen P. W., Haastrup S., Juel K. (2005) Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. *Acta Psychiatrica Scandinavica*, 111, 244-9.
306. Miotto, P., Preti A., Frezza M. (2001) Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients. *Journal of Clinical Psychopharmacology*, 21, 111-3.
307. Gerra, G., Di Petta G., D'Amore A., Iannotta P., Bardicchia F., Falorni F. et al. (2007) Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. *Clinical Neuropharmacology*, 30, 127-35.
308. Nolte, S., Wong D., Latchford G. (2007) Amphetamines for schizophrenia. *Cochrane Database of Systematic Reviews*.
309. Chen, C. K., Lin S. K., Sham P. C., Ball D., Loh E. W., Hsiao C. C. et al. (2003) Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. *Psychological Medicine*, 33, 1407-14.
310. Sweeting, M., Farrell M. (2005) Methamphetamine Psychosis: How is it Related to Schizophrenia? A Review of the Literature. *Current Psychiatry Reviews*, 1, 115-22.
311. Degner, D., Bleich S., Grohmann R., Bandelow B., Ruther E. (2000) Myocarditis associated with clozapine treatment. *Australian and New Zealand Journal of Psychiatry*, 34, 880.
312. Havens, J. R., Strathdee S. A. (2005) Antisocial Personality Disorder and Opioid Treatment Outcomes: A Review. *Addictive Disorders and Their Treatment*, 4, 85-97.
313. Messina, N. P., Wish E. D., Hoffman J. A., Nemes S. (2002) Antisocial personality disorder and TC treatment outcomes. *The American Journal of Drug and Alcohol Abuse*, 28, 197-212.
314. Benedetti, F., Sforzini L., Colombo C., Maffei C., Smeraldi E. (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. *Journal of Clinical Psychiatry*, 59, 103-7.
315. Hori, A. (1998) Pharmacotherapy for personality disorders. *iPsychiatry and Clinical Neurosciences*, 52, 13-9.
316. Gross, R., Olfson M., Gameroff M., Shea S., Feder A., Fuentes M. et al. (2002) Borderline personality disorder in primary care. *Archives of Internal Medicine*, 162, 53-60.
317. Tomasson, K., Vaglum P. (2000) Antisocial addicts: the importance of additional axis I disorders for the 28-month outcome. *European Psychiatry*, 15, 443-9.
318. Goldstein, R. B., Compton W. M., Pulay A. J., Ruan W. J., Pickering R. P., Stinson F. S. et al. (2007) Antisocial behavioral syndromes and DSM-IV drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug and Alcohol Dependence*, 90, 145-58.

319. Grant, B. F., Stinson F. S., Dawson D. A., Chou S. P., Ruan W. J., Pickering R. P. (2004) Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry*, 61, 361-8.
320. Cohen, P., Chen H., Crawford T. N., Brook J. S., Gordon K. (2007) Personality disorders in early adolescence and the development of later substance use disorders in the general population. *Drug and Alcohol Dependence*, 88 Suppl 1, S71-S84.
321. Huang, D. B., Kamat P. P., Wang J. (2006) Demographic characteristics and antisocial personality disorder of early and late onset alcoholics identified in a primary care clinic. *The American Journal on Addictions*, 15, 478-82.
322. Kovac, I., Merette C., Legault L., Dongier M., Palmour R. M. (2002) Evidence in an international sample of alcohol-dependent subjects of subgroups with specific symptom patterns of antisocial personality disorder. *Alcoholism: Clinical and Experimental Research*, 26, 1088-96.
323. Ducci, F., Enoch M. A., Funt S., Virkkunen M., Albaugh B., Goldman D. (2007) Increased anxiety and other similarities in temperament of alcoholics with and without antisocial personality disorder across three diverse populations. *Alcohol*, 41, 3-12.
324. Hunter, E. E., Powell B. J., Penick E. C., Nickel E. J., Liskow B. I., Cantrell P. J. *et al.* (2000) Comorbid psychiatric diagnosis and long-term drinking outcome. *Comprehensive Psychiatry*, 41, 334-8.
325. Krampe, H., Wagner T., Stawicki S., Bartels C., Aust C., Kroener-Herwig B. *et al.* (2006) Personality disorder and chronicity of addiction as independent outcome predictors in alcoholism treatment. *Psychiatric Services*, 57, 708-12.
326. Whiteside, S. P., Lynam D. R. (2003) Understanding the role of impulsivity and externalizing psychopathology in alcohol abuse: application of the UPPS impulsive behavior scale. *Experimental and Clinical Psychopharmacology*, 11, 210-7.
327. Malcolm, R., Ballenger J. C., Sturgis E. T., Anton R. (1989) Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. *The American Journal of Psychiatry*, 146, 617-21.
328. Myrick, H., Brady K. T., Malcolm R. (2000) Divalproex in the treatment of alcohol withdrawal. *The American Journal of Drug and Alcohol Abuse*, 26, 155-60.
329. Reoux, J. P., Saxon A. J., Malte C. A., Baer J. S., Sloan K. L. (2001) Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research*, 25, 1324-9.
330. Book, S. W., Myrick H. (2005) Novel anticonvulsants in the treatment of alcoholism. *Expert Opinion on Investigational Drugs*, 14, 371-6.
331. Soyka, M., Roesner S. (2006) New pharmacological approaches for the treatment of alcoholism. *Expert Opinion on Pharmacotherapy*, 7, 2341-53.
332. Rohsenow, D. J., Miranda R., Jr., McGeary J. E., Monti P. M. (2007) Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. *Experimental and Clinical Psychopharmacology*, 15, 272-81.
333. Darke, S., Williamson A., Ross J., Teesson M., Lynskey M. (2004) Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). *Drug and Alcohol Dependence*, 74, 77-83.
334. Darke, S., Ross J., Williamson A., Mills K. L., Havard A., Teesson M. (2007) Borderline personality disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of heroin dependence. *Addiction*, 102, 1140-6.

335. Broome, K. M., Joe G. W., Simpson D. D. (1999) HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences. *AIDS Education and Prevention*, 11, 293-306.
336. King, V. L., Kidorf M. S., Stoller K. B., Carter J. A., Brooner R. K. (2001) Influence of antisocial personality subtypes on drug abuse treatment response. *The Journal of Nervous and Mental Disease*, 189, 593-601.
337. Falck, R. S., Wang J., Siegal H. A., Carlson R. G. (2004) The prevalence of psychiatric disorder among a community sample of crack cocaine users: an exploratory study with practical implications. *The Journal of Nervous and Mental Disease*, 192, 503-7.
338. de Win, M. M., Schilt T., Reneman L., Vervaeke H., Jager G., Dijkink S. *et al.* (2006) Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. *Journal of Psychopharmacology*, 20, 226-35.
339. Hoffman, W. F., Moore M., Templin R., McFarland B., Hitzemann R. J., Mitchell S. H. (2006) Neuropsychological function and delay discounting in methamphetamine-dependent individuals. *Psychopharmacology (Berl)*, 188, 162-70.
340. Cochrane, C., Malcolm R., Brewerton T. (1998) The role of weight control as a motivation for cocaine abuse. *Addictive Behaviors*, 23, 201-7.
341. Stock, S. L., Goldberg E., Corbett S., Katzman D. K. (2002) Substance use in female adolescents with eating disorders. *Journal of Adolescent Health*, 31, 176-82.
342. Ramoz, N., Versini A., Gorwood P. (2007) Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes. *Expert Opinion on Pharmacotherapy*, 8, 2029-44.
343. Hay, P. J., Bacaltchuk J., Stefano S. (2004) Psychotherapy for bulimia nervosa and bingeing. *Cochrane Database of Systematic Reviews*, CD000562.
344. Shapiro, J. R., Berkman N. D., Brownley K. A., Sedway J. A., Lohr K. N., Bulik C. M. (2007) Bulimia nervosa treatment: a systematic review of randomized controlled trials. *The International Journal of Eating Disorders*, 40, 321-36.
345. Crow, S., Mussell M. P., Peterson C., Knopke A., Mitchell J. (1999) Prior treatment received by patients with bulimia nervosa. *The International Journal of Eating Disorders*, 25, 39-44.
346. Blinder, B. J., Cumella E. J., Sanathara V. A. (2006) Psychiatric comorbidities of female inpatients with eating disorders. *Psychosomatic Medicine*, 68, 454-62.
347. Herzog, D. B., Franko D. L., Dorer D. J., Keel P. K., Jackson S., Manzo M. P. (2006) Drug abuse in women with eating disorders. *International Journal of Eating Disorders*, 39, 364-8.
348. Patton, G. C., Coffey C., Carlin J. B., Sanci L., Sawyer S. (2008) Prognosis of adolescent partial syndromes of eating disorder. *The British Journal of Psychiatry*, 192, 294-9.
349. Piran, N., Robinson S. (2006) The association between disordered eating and substance use and abuse in women: a community-based investigation. *Women and Health*, 44, 1-20.
350. Wiederman, M. W. (1997) Adolescent Substance Use and Eating Disorders. *The Prevention Researcher*, 4, 10-1.
351. Wiederman, M. W., Pryor T. (1996) Substance use and impulsive behaviors among adolescents with eating disorders. *Addictive Behaviors*, 21, 269-72.
352. Corte, C., Stein K. F. (2000) Eating disorders and substance use; An examination of behavioral associations. *Eating Behaviors*, 1, 173-89.
353. Lacey, J. H., Evans C. D. (1986) The impulsivist: a multi-impulsive personality disorder. *British Journal of Addiction*, 81, 641-9.

354. Fischer, S., Grange D. (2007) Comorbidity and high-risk behaviors in treatment-seeking adolescents with bulimia nervosa. *The International Journal of Eating Disorders*, 40, 751-3.
355. Haug, N. A., Heinberg L. J., Guarda A. S. (2001) Cigarette smoking and its relationship to other substance use among eating disordered inpatients. *Eating and Weight Disorders*, 6, 130-9.
356. Sansone, R. A., Levitt J. L. (2002) Self-harm behaviors among those with eating disorders: an overview. *Eating Disorders*, 10, 205-13.
357. Franko, D. L., Dorer D. J., Keel P. K., Jackson S., Manzo M. P., Herzog D. B. (2005) How do eating disorders and alcohol use disorder influence each other? *The International Journal of Eating Disorders*, 38, 200-7.
358. Piran, N., Gadalla T. (2006) Eating disorders and substance abuse in Canadian women: a national study. *Addiction*, 102, 105-13.
359. Pelchat, M. L. (2002) Of human bondage: food craving, obsession, compulsion, and addiction. *Physiology and Behavior*, 76, 347-52.
360. Curran, H. V., Robjant K. (2006) Eating attitudes, weight concerns and beliefs about drug effects in women who use ecstasy. *Journal of Psychopharmacology*, 20, 425-31.
361. Nagata, T., Oshima J., Wada A., Yamada H., Kiriike N. (2003) Repetitive self-mutilation among Japanese eating disorder patients with drug use disorder: comparison with patients with methamphetamine use disorder. *The Journal of Nervous and Mental Disease*, 191, 319-23.
362. Patton, G. C., Coffey C., Sawyer S. M. (2003) The outcome of adolescent eating disorders: findings from the Victorian Adolescent Health Cohort Study. *European Child and Adolescent Psychiatry*, 12 Suppl 1, 125-129.
363. Bulik, C. M., Klump K. L., Thornton L., Kaplan A. S., Devlin B., Fichter M. M. *et al.* (2004) Alcohol use disorder comorbidity in eating disorders: a multicenter study. *Journal of Clinical Psychiatry*, 65, 1000-6.
364. Alvarez-Moya, E. M., Jimenez-Murcia S., Granero R., Vallejo J., Krug I., Bulik C. M. *et al.* (2007) Comparison of personality risk factors in bulimia nervosa and pathological gambling. *Comprehensive Psychiatry*, 48, 452-7.
365. Engwall, D., Hunter R., Steinberg M. (2004) Gambling and other risk behaviors on university campuses. *Journal of American College Health*, 52, 245-55.
366. Fernandez-Aranda, F., Jimenez-Murcia S., Alvarez-Moya E. M., Granero R., Vallejo J., Bulik C. M. (2006) Impulse control disorders in eating disorders: clinical and therapeutic implications. *Comprehensive Psychiatry*, 47, 482-8.
367. Huang, J. H., Jacobs D. F., Derevensky J. L., Gupta R., Paskus T. S. (2007) Gambling and health risk behaviors among U.S. college student-athletes: findings from a national study. *Journal of Adolescent Health*, 40, 390-7.
368. Davis, C., Claridge G. (1998) The eating disorders as addiction: a psychobiological perspective. *Addictive Behaviors*, 23, 463-75.
369. Cooper, S. J. (2004) Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. *European Journal of Pharmacology*, 500, 37-49.
370. Adams, T. B., Araas T. E. (2006) Purging and alcohol-related effects in college women. *The International Journal of Eating Disorders*, 39, 240-4.
371. Neumark-Sztainer, D., Story M., Dixon L. B., Murray D. M. (1998) Adolescents engaging in unhealthy weight control behaviors: are they at risk for other health-compromising behaviors? *American Journal of Public Health*, 88, 952-5.
372. Conason, A. H., Sher L. (2006) Alcohol use in adolescents with eating disorders. *International Journal of Adolescent Medicine and Health*, 18, 31-6.

373. O'Malley, S. S., Sinha R., Grilo C. M., Capone C., Farren C. K., McKee S. A. *et al.* (2007) Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. *Alcoholism: Clinical and Experimental Research*, 31, 625-34.
374. Glass, M. J., Billington C. J., Levine A. S. (1999) Opioids and food intake: distributed functional neural pathways. *Neuropeptides*, 33, 360-8.
375. Mercer, M. E., Holder M. D. (1997) Food cravings, endogenous opioid peptides, and food intake: a review. *Appetite*, 29, 325-52.
376. Cooper, S. J. (2005) Palatability-dependent appetite and benzodiazepines: new directions from the pharmacology of GABA(A) receptor subtypes. *Appetite*, 44, 133-50.
377. Singh, B. S. (1998) Managing somatoform disorders. *Medical Journal of Australia*, 168, 572-7.
378. Rosendal, M., Bro F., Sokolowski I., Fink P., Toft T., Olesen F. (2005) A randomised controlled trial of brief training in assessment and treatment of somatisation: effects on GPs' attitudes. *Family Practice*, 22, 419-27.
379. Escobar, J. I. (1995) Transcultural aspects of dissociative and somatoform disorders. *Psychiatric Clinics of North America*, 18, 555-69.
380. Allen, L. A., Woolfolk R. L., Escobar J. I., Gara M. A., Hamer R. M. (2006) Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. *Archives of Internal Medicine*, 166, 1512-8.
381. Barsky, A. J., Ahern D. K. (2004) Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. *The Journal of the American Medical Association*, 291, 1464-70.
382. Buwalda, F. M., Bouman T. K., van Duijn M. A. (2007) Psychoeducation for hypochondriasis: a comparison of a cognitive-behavioural approach and a problem-solving approach. *Behaviour Research and Therapy*, 45, 887-99.
383. Clark, D. M., Salkovskis P. M., Hackmann A., Wells A., Fennell M., Ludgate J. *et al.* (1998) Two psychological treatments for hypochondriasis. A randomised controlled trial. *The British Journal of Psychiatry*, 173, 218-25.
384. Escobar, J. I., Gara M. A., Diaz-Martinez A. M., Interian A., Warman M., Allen L. A. *et al.* (2007) Effectiveness of a time-limited cognitive behavior therapy type intervention among primary care patients with medically unexplained symptoms. *Annals of Family Medicine*, 5, 328-35.
385. Magarinos, M., Zafar U., Nissenon K., Blanco C. (2002) Epidemiology and treatment of hypochondriasis. *CNS Drugs*, 16, 9-22.
386. Visser, S., Bouman T. K. (2001) The treatment of hypochondriasis: exposure plus response prevention vs cognitive therapy. *Behaviour Research and Therapy*, 39, 423-42.
387. Pols, R. G., Holmwood C., Battersby M. (1999) Understanding somatisation and somatisation disorders: A handbook for healthcare workers.
388. Aragones, E., Labad A., Pinol J. L., Lucena C., Alonso Y. (2005) Somatized depression in primary care attenders. *Journal of Psychosomatic Research*, 58, 145-51.
389. Allen, L. A., Gara M. A., Escobar J. I., Waitzkin H., Silver R. C. (2001) Somatization: a debilitating syndrome in primary care. *Psychosomatics*, 42, 63-7.
390. Creed, F., Barsky A. (2004) A systematic review of the epidemiology of somatisation disorder and hypochondriasis. *Journal of Psychosomatic Research*, 56, 391-408.
391. Gureje, O., Von Korff M., Kola L., Demyttenaere K., He Y., Posada-Villa J. *et al.* (2008) The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. *Pain*, 135, 82-91.

392. Haug, T. T., Mykletun A., Dahl A. A. (2004) The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. *Psychological Medicine*, 66, 845-51.
393. Escobar, J. I., Gara M., Silver R. C., Waitzkin H., Holman A., Compton W. (1998) Somatisation disorder in primary care. *The British Journal of Psychiatry*, 173, 262-6.
394. Escobar, J. I., Gara M., Waitzkin H., Silver R. C., Holman A., Compton W. (1998) DSM-IV hypochondriasis in primary care. *General Hospital Psychiatry*, 20, 155-9.
395. Gureje, O., Simon G. E., Von Korff M. (2001) A cross-national study of the course of persistent pain in primary care. *Pain*, 92, 195-200.
396. Leiknes, K. A., Finset A., Moum T., Sandanger I. (2007) Current somatoform disorders in Norway: prevalence, risk factors and comorbidity with anxiety, depression and musculoskeletal disorders. *Social Psychiatry and Psychiatric Epidemiology*, 42, 698-710.
397. Mergl, R., Seidscheck I., Allgaier A., Moller H., Hegerl U., Henkel V. (2007) Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. *Depression and Anxiety*, 24, 185-95.
398. Stordal, E., Bjelland I., Dahl A. A., Mykletun A. (2003) Anxiety and depression in individuals with somatic health problems. The Nord-Trondelag Health Study (HUNT). *Scandinavian Journal of Primary Health Care*, 21, 136-41.
399. Rief, W., Nanke A., Emmerich J., Bender A., Zech T. (2004) Causal illness attributions in somatoform disorders: associations with comorbidity and illness behavior. *Journal of Psychosomatic Research*, 57, 367-71.
400. Henningsen, P., Jakobsen T., Schiltenswolf M., Weiss M. G. (2005) Somatization revisited: diagnosis and perceived causes of common mental disorders. *The Journal of Nervous and Mental Disease*, 193, 85-92.
401. Smith, R. C., Gardiner J. C., Lyles J. S., Sirbu C., Dwamena F. C., Hodges A. et al. (2005) Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. *Psychosomatic Medicine*, 67, 123-9.
402. Hansen, G. R., Streltzer J. (2005) The psychology of pain. *Emergency Medicine Clinics of North America*, 23, 339-48.
403. Ballantyne, J. C., LaForge K. S. (2007) Opioid dependence and addiction during opioid treatment of chronic pain. *Pain*, 129, 235-55.
404. Hasin, D., Katz H. (2007) Somatoform and substance use disorders. *Psychological Medicine*, 69, 870-5.
405. Molloy, A. R., Nicholas M. K., Asghari A., Beeston L. R., Dehghani M., Cousins M. J. et al. (2006) Does a combination of intensive cognitive-behavioral pain management and a spinal implantable device confer any advantage? A preliminary examination. *Pain Practice*, 6, 96-103.
406. Kroenke, K., Messina N., 3rd, Benattia I., Graepel J., Musgnung J. (2006) Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. *Journal of Clinical Psychiatry*, 67, 72-80.
407. Voon, V., Lang A. E. (2005) Antidepressant treatment outcomes of psychogenic movement disorder. *Journal of Clinical Psychiatry*, 66, 1529-34.
408. Rhudy, J. L., Dubbert P. M., Parker J. D., Burke R. S., Williams A. E. (2006) Affective modulation of pain in substance-dependent veterans. *Pain Medicine*, 7, 483-500.
409. Warmis, C. A., Turner J. A., Marshall H. M., Cardenas D. D. (2002) Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. *The Clinical Journal of Pain*, 18, 154-63.

410. Campbell, F. A., Tramer M. R., Carroll D., Reynolds D. J., Moore R. A., McQuay H. J. (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *British Medical Journal*, 323, 13-6.
411. Corey, S. (2005) Recent developments in the therapeutic potential of cannabinoids. *Puerto Rico Health Sciences Journal*, 24, 19-26.
412. Hall, W., Degenhardt L., Lynskey M. The health and psychological effects of cannabis use. In: Ageing Ha, ed. 2nd ed. Canberra 2001.
413. Robson, P. (2005) Human studies of cannabinoids and medicinal cannabis. *Handbook of Experimental Pharmacology*, 719-56.
414. Williamson, E. M., Evans F. J. (2000) Cannabinoids in clinical practice. *Drugs*, 60, 1303-14.
415. Grant, J. E., Menard W., Pagano M. E., Fay C., Phillips K. A. (2005) Substance use disorders in individuals with body dysmorphic disorder. *Journal of Clinical Psychiatry*, 66, 309-16; quiz 404-5.
416. Ware, M. A., Doyle C. R., Woods R., Lynch M. E., Clark A. J. (2003) Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain*, 102, 211-6.
417. Breckenridge, J., Clarke J. D. (2003) Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. *The Journal of Pain*, 4, 344-50.
418. Edlund, M. J., Sullivan M., Steffick D., Harris K. M., Wells K. B. (2007) Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? *Pain Medicine*, 8, 647-56.
419. Doherty, M., White J. M., Somogyi A. A., Bochner F., Ali R., Ling W. (2001) Hyperalgesic responses in methadone maintenance patients. *Pain*, 90, 91-6.
420. Webster, L. R., Webster R. M. (2005) Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. *Pain Medicine*, 6, 432-42.
421. Brauer, L. H., De Wit H. (1997) High dose pimozone does not block amphetamine-induced euphoria in normal volunteers. *Pharmacology Biochemistry and Behavior*, 56, 265-72.
422. Degenhardt, L., Topp L. (2003) 'Crystal meth' use amongst polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. *International Journal of Drug Policy*, 14, 17-24.
423. Blockmans, D., Persoons P., Van Houdenhove B., Bobbaers H. (2006) Does methylphenidate reduce the symptoms of chronic fatigue syndrome? *The American Journal of Medicine*, 119, 167 e23-30.
424. Olson, L. G., Ambrogetti A., Sutherland D. C. (2003) A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. *Psychosomatics*, 44, 38-43.
425. Randall, D. C., Cafferty F. H., Shneerson J. M., Smith I. E., Llewelyn M. B., File S. E. (2005) Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. *Journal of Psychopharmacology*, 19, 647-60.
426. Martin, P. R., Weinberg B. A., Bealer B. K. Pathological Gambling. *Healing Addiction: An integrated pharmacopsychosocial approach to treatment*. Hoboken: John Wiley & Sons Inc 2007:149-59.
427. Moreyra, P., Ibanez A., Saiz-Ruiz J., Nissenson K., Blanco C. (2000) Review of the phenomenology, etiology and treatment of pathological gambling. *German Journal of Psychiatry*, 3, 37-52.
428. Pallanti, S. Pathological Gambling. *Clinical Manual of Impulse-Control Disorders* 2006:251-89.
429. Volberg, R. A. (2002) The epidemiology of pathological gambling. *Psychiatric Annals*, 32, 171-8.
430. Petry, N. M. Introduction. *Pathological Gambling: Etiology, comorbidity, and treatment*. Washington: American Psychological Association 2005:3-8.

431. Blanco, C., Hasin D. S., Petry N., Stinson F. S., Grant B. F. (2006) Sex differences in subclinical and DSM-IV pathological gambling: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychological Medicine*, 36, 943-53.
432. Kausch, O. (2003) Patterns of substance abuse among treatment-seeking pathological gamblers. *Journal of Substance Abuse Treatment*, 25, 263-70.
433. Ladd, G. T., Petry N. M. (2003) A comparison of pathological gamblers with and without substance abuse treatment histories. *Experimental and Clinical Psychopharmacology*, 11, 202-9.
434. Pasternak, A. V. t., Fleming M. F. (1999) Prevalence of gambling disorders in a primary care setting. *Archives of Family Medicine*, 8, 515-20.
435. Petry, N. M., Stinson F. S., Grant B. F. (2005) Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Journal of Clinical Psychiatry*, 66, 564-74.
436. Toneatto, T., Brennan J. (2002) Pathological gambling in treatment-seeking substance abusers. *Addictive Behaviors*, 27, 465-9.
437. Magoon, M. E., Gupta R., Derevensky J. L. (2005) Juvenile delinquency and adolescent gambling. *Criminal Justice and Behavior*, 32, 690-712.
438. Dell'Osso, B., Altamura A. C., Allen A., Marazziti D., Hollander E. (2006) Epidemiologic and clinical updates on impulse control disorders: a critical review. *European Archives of Psychiatry and Clinical Neuroscience*, 256, 464-75.
439. Hall, G. W., Carriero N. J., Takushi R. Y., Montoya I. D., Preston K. L., Gorelick D. A. (2000) Pathological gambling among cocaine-dependent outpatients. *The American Journal of Psychiatry*, 157, 1127-33.
440. Petry, N. M., Tawfik Z. (2001) Comparison of problem-gambling and non-problem-gambling youths seeking treatment for marijuana abuse. *Journal of the American Academy of Child and Adolescent Psychiatry*, 40, 1324-31.
441. Ladouceur, R., Sylvain C., Boutin C., Lachance S., Doucet C., Leblond J. *et al.* (2001) Cognitive treatment of pathological gambling. *The Journal of Nervous and Mental Disease*, 189, 774-80.
442. Sylvain, C., Ladouceur R., Boisvert J. M. (1997) Cognitive and behavioral treatment of pathological gambling: a controlled study. *Journal of Consulting and Clinical Psychology*, 65, 727-32.
443. Toneatto, T., Ladoceur R. (2003) Treatment of pathological gambling: a critical review of the literature. *Psychology of Addictive Behaviors*, 17, 284-92.
444. Hodgins, D. C., Currie S. R., el-Guebaly N. (2001) Motivational enhancement and self-help treatments for problem gambling. *Journal of Consulting and Clinical Psychology*, 69, 50-7.
445. Pallesen, S., Molde H., Arnestad H. M., Laberg J. C., Skutle A., Iversen E. *et al.* (2007) Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. *Journal of Clinical Psychopharmacology*, 27, 357-64.
446. Hollander, E., Buchalter A. J., DeCaria C. M. (2000) Pathological gambling. *Psychiatric Clinics of North America*, 23, 629-42.
447. Kim, S. W., Grant J. E., Eckert E. D., Faris P. L., Hartman B. K. (2006) Pathological gambling and mood disorders: clinical associations and treatment implications. *Journal of Affective Disorders*, 92, 109-16.
448. Hollander, E., DeCaria C. M., Finkell J. N., Begaz T., Wong C. M., Cartwright C. (2000) A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. *Biological Psychiatry*, 47, 813-7.

449. Kim, S. W. (2002) Review of published studies on drug treatments for PGD. *Minnesota Medicine*, 85, 51-2.
450. Zimmerman, M., Breen R. B., Posternak M. A. (2002) An open-label study of citalopram in the treatment of pathological gambling. *Journal of Clinical Psychiatry*, 63, 44-8.
451. Hollander, E., DeCaria C. M., Mari E., Wong C. M., Mosovich S., Grossman R. *et al.* (1998) Short-term single-blind fluvoxamine treatment of pathological gambling. *The American Journal of Psychiatry*, 155, 1781-3.
452. Grant, J. E., Kim S. W., Potenza M. N. (2003) Advances in the pharmacological treatment of pathological gambling. *Journal of Gambling Studies*, 19, 85-109.
453. Kim, S. W., Grant J. E. (2001) The psychopharmacology of pathological gambling. *Seminars in Clinical Neuropsychiatry*, 6, 184-94.
454. Dannon, P. N., Lowengrub K., Musin E., Gonopolski Y., Kotler M. (2005) Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. *Journal of Psychopharmacology*, 25, 593-6.
455. Kim, S. W. (1998) Opioid antagonists in the treatment of impulse-control disorders. *Journal of Clinical Psychiatry*, 59, 159-64.
456. Kim, S. W., Grant J. E., Adson D. E., Shin Y. C. (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. *Biological Psychiatry*, 49, 914-21.
457. Pallanti, S., Quercioli L., Sood E., Hollander E. (2002) Lithium and valproate treatment of pathological gambling: a randomized single-blind study. *Journal of Clinical Psychiatry*, 63, 559-64.
458. Dannon, P. N., Lowengrub K., Gonopolski Y., Musin E., Kotler M. (2005) Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. *Clinical Neuropharmacology*, 28, 6-10.
459. Dannon, P. N., Lowengrub K., Aizer A., Kotler M. (2006) Pathological gambling: comorbid psychiatric diagnoses in patients and their families. *The Israel Journal of Psychiatry and Related Science*, 43, 88-92.
460. Dannon, P. N., Lowengrub K., Shalgi B., Sasson M., Tuson L., Saphir Y. *et al.* (2006) Dual psychiatric diagnosis and substance abuse in pathological gamblers: a preliminary gender comparison study. *Journal of Addictive Diseases*, 25, 49-54.
461. Martins, S. S., Storr C. L., Ialongo N. S., Chilcoat H. D. (2007) Mental health and gambling in urban female adolescents. *Journal of Adolescent Health*, 40, 463-5.
462. Zimmerman, M., Chelminski I., Young D. (2006) Prevalence and Diagnostic Correlates of DSM-IV Pathological Gambling in Psychiatric Outpatients. *Journal of Gambling Studies*, 22, 255-62.
463. Clarke, D. (2003) Gambling and the trait of addiction in a sample of New Zealand university students. *New Zealand Journal of Psychology*, 32, 39-48.
464. Toneatto, T., Skinner W., Dragonetti R. (2002) Patterns of substance use in treatment-seeking problem gamblers: impact on treatment outcomes. *Journal of Clinical Psychology*, 58, 853-9.
465. Fernandez-Montalvo, J., Echeburua E. (2004) Pathological gambling and personality disorders: an exploratory study with the IPDE. *Journal of Personality Disorders*, 18, 500-5.
466. Gerdner, R., Svensson K. (2003) Predictors of gambling problems among male adolescents. *International Journal of Social Welfare*, 12, 182-92.
467. Langenbucher, J., Bavly L., Labouvie E., Sanjuan P. M., Martin C. S. (2001) Clinical features of pathological gambling in an addictions treatment cohort. *Psychology of Addictive Behaviors*, 15, 77-9.
468. Slutske, W. S., Caspi A., Moffitt T. E., Poulton R. (2005) Personality and problem gambling: a prospective study of a birth cohort of young adults. *Archives of General Psychiatry*, 62, 769-75.

469. Morasco, B. J., Pietrzak R. H., Blanco C., Grant B. F., Hasin D., Petry N. M. (2006) Health problems and medical utilization associated with gambling disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychosomatic Medicine*, 68, 976-84.
470. Kaminer, Y., Burleson J. A., Jadamec A. (2002) Gambling behavior in adolescent substance abuse. *Substance Abuse*, 23, 191-8.
471. McNeilly, D. P., Burke W. J. (2002) Disposable time and dispossable income: Problem casino gambling behavior in older adults. *Journal of Clinical Geropsychology*, 8, 75-85.
472. Battersby, M., Tolchard B., Scurrah M., Thomas L. (2006) Suicide ideation and behaviour in people with pathological gambling attending a treatment service. *International Journal of Mental Health Addiction*, 4, 233-46.
473. Biddle, D., Hawthorne G., Forbes D., Coman G. (2005) Problem gambling in Australian PTSD treatment-seeking veterans. *Journal of Traumatic Stress*, 18, 759-67.
474. Dannon, P. N., Lowengrub K., Sasson M., Shalgi B., Tuson L., Saphir Y. *et al.* (2004) Comorbid psychiatric diagnoses in kleptomania and pathological gambling: a preliminary comparison study. *European Psychiatry*, 19, 299-302.
475. Feigelman, W., Gorman B. S., Lesieur H. (2006) Examining the relationship between at-risk gambling and suicidality in a national representative sample of young adults. *Suicide and Life-Threatening Behavior*, 36, 396-408.
476. Maccallum, F., Blaszczynski A. (2003) Pathological gambling and suicidality: an analysis of severity and lethality. *Suicide and Life-Threatening Behavior*, 33, 88-98.
477. Martins, S. S., Tavares H., da Silva Lobo D. S., Galetti A. M., Gentil V. (2004) Pathological gambling, gender, and risk-taking behaviors. *Addictive Behaviors*, 29, 1231-5.
478. Shaffer, H. J., Vander Bilt J., Hall M. N. (1999) Gambling, drinking, smoking and other health risk activities among casino employees. *American Journal of Industrial Medicine*, 36, 365-78.
479. McIntyre, R. S., McElroy S. L., Konarski J. Z., Soczynska J. K., Wilkins K., Kennedy S. H. (2007) Problem gambling in bipolar disorder: results from the Canadian Community Health Survey. *Journal of Affective Disorders*, 102, 27-34.
480. Ledgerwood, D. M., Petry N. M. (2006) Posttraumatic stress disorder symptoms in treatment-seeking pathological gamblers. *Journal of Traumatic Stress*, 19, 411-6.
481. Frost, R. O., Meagher B. M., Riskind J. H. (2001) Obsessive-compulsive features in pathological lottery and scratch-ticket gamblers. *Journal of Gambling Studies*, 17, 5-19.
482. Cunningham-Williams, R. M., Abdallah A. B., Callahan C., Cottler L. (2007) Problem gambling and violence among community-recruited female substance abusers. *Psychology of Addictive Behaviors*, 21, 239-43.
483. Ibanez, A., Blanco C., Donahue E., Lesieur H. R., Perez de Castro I., Fernandez-Piqueras J. *et al.* (2001) Psychiatric comorbidity in pathological gamblers seeking treatment. *The American Journal of Psychiatry*, 158, 1733-5.
484. Grant, J. E., Kim S. W. (2003) Comorbidity of impulse control disorders in pathological gamblers. *Acta Psychiatrica Scandinavica*, 108, 203-7.
485. Kausch, O. (2003) Suicide attempts among veterans seeking treatment for pathological gambling. *Journal of Clinical Psychiatry*, 64, 1031-8.
486. Hollander, E., Pallanti S., Allen A., Sood E., Baldini Rossi N. (2005) Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? *The American Journal of Psychiatry*, 162, 137-45.

487. Grant, J. E., Potenza M. N. (2006) Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. *International Clinical Psychopharmacology*, 21, 203-9.
488. Maccallum, F., Blaszczynski A. (2001) Pathological gambling and comorbid substance use. *Australian and New Zealand Journal of Psychiatry*, 36, 411-5.
489. Sellman, J. D., Adamson S., Robertson P., Sullivan S., Coverdale J. (2002) Gambling in mild-moderate alcohol-dependent outpatients. *Substance Use and Misuse*, 37, 199-213.
490. Lejoyeux, M., Feuche N., Loi S., Solomon J., Ades J. (1999) Study of impulse-control disorders among alcohol-dependent patients. *Journal of Clinical Psychiatry*, 60, 302-5.
491. Kyngdon, A., Dickerson M. (1999) An experimental study of the effect of prior alcohol consumption on a simulated gambling activity. *Addiction*, 94, 697-707.
492. Phillips, J. G., Ogeil R. P. (2007) Alcohol consumption and computer blackjack. *The Journal of General Psychology*, 134, 333-53.
493. Potenza, M. N., Steinberg M. A., Wu R. (2005) Characteristics of gambling helpline callers with self-reported gambling and alcohol use problems. *Journal of Gambling Studies*, 21, 233-54.
494. Crockford, D. N. (1998) Naltrexone in the treatment of pathological gambling. *Canadian Journal of Psychiatry*, 43, 86.
495. Ledgerwood, D. M., Downey K. K. (2002) Relationship between problem gambling and substance use in a methadone maintenance population. *Addictive Behaviors*, 27, 483-91.
496. Weinstock, J., Blanco C., Petry N. M. (2006) Health correlates of pathological gambling in a methadone maintenance clinic. *Experimental and Clinical Psychopharmacology*, 14, 87-93.
497. Comer, S. D., Sullivan M. A., Yu E., Rothenberg J. L., Kleber H. D., Kampman K. *et al.* (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Archives of General Psychiatry*, 63, 210-8.
498. Pirastu, R., Fais R., Messina M., Bini V., Spiga S., Falconieri D. *et al.* (2006) Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. *Drug and Alcohol Dependence*, 83, 163-8.
499. Deakin, J. B., Aitken M. R., Dowson J. H., Robbins T. W., Sahakian B. J. (2004) Diazepam produces disinhibitory cognitive effects in male volunteers. *Psychopharmacology (Berl)*, 173, 88-97.
500. Fann, J. R., Leonetti A., Jaffe K., Katon W. J., Cummings P., Thompson R. S. (2002) Psychiatric illness and subsequent traumatic brain injury: a case control study. *Journal of Neurology, Neurosurgery, and Psychiatry*, 72, 615-20.
501. Teasdale, T. W., Engberg A. W. (2001) Suicide after traumatic brain injury: a population study. *Journal of Neurology, Neurosurgery, and Psychiatry*, 71, 436-40.
502. Mann, J. J., Waternaux C., Haas G. L., Malone K. M. (1999) Toward a clinical model of suicidal behavior in psychiatric patients. *The American Journal of Psychiatry*, 156, 181-9.
503. Deb, S., Lyons I., Koutzoukis C., Ali I., McCarthy G. (1999) Rate of psychiatric illness 1 year after traumatic brain injury. *The American Journal of Psychiatry*, 156, 374-8.
504. Hibbard, M. R., Uysal S., Kepler K., Bogdany J., Silver J. (1998) Axis I psychopathology in individuals with traumatic brain injury. *The Journal of Head Trauma Rehabilitation*, 13, 24-39.
505. Anstey, K. J., Butterworth P., Jorm A. F., Christensen H., Rodgers B., Windsor T. D. (2004) A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms. *Journal of Clinical Epidemiology*, 57, 1202-9.

506. Silver, J. M., Kramer R., Greenwald S., Weissman M. (2001) The association between head injuries and psychiatric disorders: findings from the New Haven NIMH Epidemiologic Catchment Area Study. *Brain Injury*, 15, 935-45.
507. Felde, A. B., Westermeyer J., Thuras P. (2006) Co-morbid traumatic brain injury and substance use disorder: childhood predictors and adult correlates. *Brain Injury*, 20, 41-9.
508. Jorge, R. E., Starkstein S. E., Arndt S., Moser D., Crespo-Facorro B., Robinson R. G. (2005) Alcohol misuse and mood disorders following traumatic brain injury. *Archives of General Psychiatry*, 62, 742-9.
509. Ries, R. K., Yuodelis-Flores C., Comtois K. A., Roy-Byrne P. P., Russo J. E. (2008) Substance-induced suicidal admissions to an acute psychiatric service: characteristics and outcomes. *Journal of Substance Abuse Treatment*, 34, 72-9.
510. Simpson, G., Tate R. (2002) Suicidality after traumatic brain injury: demographic, injury and clinical correlates. *Psychological Medicine*, 32, 687-97.
511. Timonen, M., Miettunen J., Hakko H., Zitting P., Veijola J., von Wendt L. *et al.* (2002) The association of preceding traumatic brain injury with mental disorders, alcoholism and criminality: the Northern Finland 1966 Birth Cohort Study. *Psychiatry Research*, 113, 217-26.
512. Hibbard, M. R., Ashman T. A., Spielman L. A., Chun D., Charatz H. J., Melvin S. (2004) Relationship between depression and psychosocial functioning after traumatic brain injury. *Archives of Physical Medicine and Rehabilitation*, 85, S43-S53.
513. Holsinger, T., Steffens D. C., Phillips C., Helms M. J., Havlik R. J., Breitner J. C. *et al.* (2002) Head injury in early adulthood and the lifetime risk of depression. *Archives of General Psychiatry*, 59, 17-22.
514. Koponen, S., Taiminen T., Portin R., Himanen L., Isoniemi H., Heinonen H. *et al.* (2002) Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. *The American Journal of Psychiatry*, 159, 1315-21.
515. Seel, R. T., Kreutzer J. S. (2003) Depression assessment after traumatic brain injury: an empirically based classification method. *Archives of Physical Medicine and Rehabilitation*, 84, 1621-8.
516. Seel, R. T., Kreutzer J. S., Rosenthal M., Hammond F. M., Corrigan J. D., Black K. (2003) Depression after traumatic brain injury: a National Institute on Disability and Rehabilitation Research Model Systems multicenter investigation. *Archives of Physical Medicine and Rehabilitation*, 84, 177-84.
517. Rapoport, M. J., McCullagh S., Streiner D., Feinstein A. (2003) The clinical significance of major depression following mild traumatic brain injury. *Psychosomatics*, 44, 31-7.
518. Underhill, A. T., Lobello S. G., Stroud T. P., Terry K. S., Devivo M. J., Fine P. R. (2003) Depression and life satisfaction in patients with traumatic brain injury: a longitudinal study. *Brain Injury*, 17, 973-82.
519. Simpson, G. K., Tate R. L. (2007) Preventing suicide after traumatic brain injury: implications for general practice. *Medical Journal of Australia*, 187, 229-32.
520. Tate, R., Simpson G., Flanagan S., Coffey M. (1997) Completed suicide after traumatic brain injury. *The Journal of Head Trauma Rehabilitation*, 12, 16-28.
521. Kalsotra, A., Turman C. M., Dash P. K., Strobel H. W. (2003) Differential effects of traumatic brain injury on the cytochrome p450 system: a perspective into hepatic and renal drug metabolism. *Journal of Neurotrauma*, 20, 1339-50.
522. Wroblewski, B. A., Joseph A. B., Cornblatt R. R. (1996) Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study. *Journal of Clinical Psychiatry*, 57, 582-7.

523. Lee, H., Kim S. W., Kim J. M., Shin I. S., Yang S. J., Yoon J. S. (2005) Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. *Human Psychopharmacology*, 20, 97-104.
524. Perna, R. (2006) Brain injury: benzodiazepines, antipsychotics, and functional recovery. *The Journal of Head Trauma Rehabilitation*, 21, 82-4.
525. Fann, J. R., Uomoto J. M., Katon W. J. (2000) Sertraline in the treatment of major depression following mild traumatic brain injury. *Journal of Neuropsychiatry and Clinical Neurosciences*, 12, 226-32.
526. Turner-Stokes, L., Hassan N., Pierce K., Clegg F. (2002) Managing depression in brain injury rehabilitation: the use of an integrated care pathway and preliminary report of response to sertraline. *Clinical Rehabilitation*, 16, 261-8.
527. Soo, C., Tate R. (2007) Psychological treatment for anxiety in people with traumatic brain injury. *Cochrane Database of Systematic Reviews*, CD005239.
528. DASSA, D. a. A. S. S. A. (2005) Alcohol Related Brain Injury: A Guide for General Practitioners and Other Health Workers. Adelaide: Drug and Alcohol Services South Australia.
529. Trevena, L., Cameron I., Porwal M. (2004) Clinical Practice Guidelines for the Care of People Living with Traumatic Brain Injury in the Community. Sydney: The University of Sydney.
530. Isbister, G. K., Buckley N. A., Whyte I. M. (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. *Medical Journal of Australia*, 187, 361-5.